Zenith Epigenetics Appoints Dr. Norman C.W. Wong to the Board of Directors

Calgary, Alberta, November 30, 2015 – Zenith Epigenetics Corp. (“Zenith” or the “Company”) today announced that it has appointed Dr. Norman C.W. Wong to its Board of Directors to replace Dr. Peter Johann. Dr. Wong comes to Zenith with a wealth of experience as co-founder of Resverlogix, with expertise in the fields of endocrinology and molecular biology.

Dr. Wong remarked, “I am very excited to be joining Zenith Epigenetics’ board of directors. Zenith’s long standing expertise in epigenetics and the advanced stage of the R&D portfolio makes this a very exciting time to join the company.”

Donald J. McCaffrey, president and chief executive officer stated, “We extend our gratitude to Dr. Johann for guiding Zenith from its initial days as a newly-incorporated company to today as we embark on our investigational new drug application (IND) for our lead BET bromodomain inhibitor in oncology.”

About Zenith

Zenith Epigenetics Corp. is a biotechnology company focused on the discovery and development of novel therapeutics by applying its proprietary epigenetics platform. Zenith’s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well.

For further information, please contact:

Donald McCaffrey

President and CEO

Zenith Epigenetics Corp.

Phone: 587-390-7865

Email: info@zenithepigenetics.com